no New path needed for NuPathe,,,parts I liked from transcript
"We remain on target to launch ZECUITY in the fourth quarter of this year."...." Now we are laser focused on securing global commercial partners and preparing for launch. The U.S. commercial partner will enable us to maximize the commercial opportunity for ZECUITY. There is a core target audience of approximately 10,000 neurologists and headache specialists who account for approximately 1/3 of triptan prescription volume. Additionally, there's a discrete segment of the primary care market for which approximately 30,000 primary care physicians can expand our reach to 2/3 of the triptan prescription volume."